Dr. Bass is an Attending Physician in the Division of Rheumatology at Hospital for Special Surgery and a Professor of Clinical Medicine at Weill Cornell Medicine. She specializes in the treatment of patients with autoimmune side effects of cancer immunotherapy, and also sees patients with vasculitis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and autoimmune eye disease. Dr. Bass co-directs the HSS Checkpoint inhibitor associated arthritis registry and is doing translational research to better understand this condition.
Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may have coverage subject to the availability of 'out-of-network' benefits.
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College
MD, Columbia College of Physicians and Surgeons, New York
Columbia Presbyterian Medical Center
New York University Medical Center/Hospital for Joint Diseases
Internal Medicine, 1988
Rheumatology, 1992, 2002, 2012
Castle Connolly Top Regional Doctor, 2014-2021
New York Magazine Top Doctors, 2014-2021
Castle Connolly Top Doctors in New York Metro Area, 2015-2021
Bass AR. “Venous Thromboembolism and Orthopedic Surgery” in Perioperative Care of the Orthopedic Patient. MacKenzie CR, Cornell CN, Memtsoudis SG eds. Springer 2019
Bass AR, Rogatsky I. Immunomodulatory drugs. Cecil’s Textbook of Medicine. 26th edition. Goldman, Schafer ed. Elsevier 2019
Chan KK, Bass AR. Autoimmune Complications of Immunotherapy: Pathophysiology and Management. British Medical Journal 2020 Apr 6. PMID: 32253223
Reid PD, Cifu AS, Bass AR. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021 Feb 2;325(5):482-483. doi: 10.1001/jama.2020.17308. PMID: 33528524.
Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol. 2021 Mar 8. doi: 10.1038/s41584-021-00584-4. Epub ahead of print. PMID: 33686279.
Bass AR, Zhang Y, Mehta B, Do HT, Russell LA, Sculco PK, Goodman SM. Periprosthetic Joint Infection Is Associated with an Increased Risk of Venous Thromboembolism Following Revision Total Knee Replacement: An Analysis of Administrative Discharge Data. J Bone Joint Surg Am. 2021 Mar 22. doi: 10.2106/JBJS.20.01486. Epub ahead of print. PMID: 33750744.
Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, Calabrese C, Gravallese EM, Harpaz R, Kroger A, Sadun RE, Turner AS, Anderson Williams E, Mikuls TR. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases - Version 1. Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734. Online ahead of print. PMID: 33728796
Ghosh N, Chan KK, Jivanelli B, Bass AR. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review. J Clin Rheumatol. 2021 Aug 5. doi: 10.1097/RHU.0000000000001777. Epub ahead of print. PMID: 34371516.
Bass AR, Do HT, Mehta B, Lyman S, Mirza SZ, Parks M, Figgie M, Mandl LA, Goodman SM. Assessment of Racial Disparities in the Risks of Septic and Aseptic Revision Total Knee Replacements. JAMA Netw Open. 2021 Jul 1;4(7):e2117581. PMID: 34287631; PMCID: PMC8295735.
Runci Wang, Karmela Kim Chan, Amy Cunningham-Bussel, Gregory Vitone, Aidan Tirpack, Caroline Benson, Gregory Keras, A. Helena Jonsson, Michael B. Brenner, Laura T. Donlin, Anne R. Bass*, Deepak A. Rao* * co-senior authors. Checkpoint Inhibitor-Associated Arthritis Synovial Fluid Mononuclear Cells: High-Dimensional Analyses Reveals a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type 1 IFN. Plenary ACR Convergence, November 2020
Ghosh N, Zhu C, Chan K, Postow M, Bass A. Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events. ACR Convergence, November 2021
Ghosh N, Jannat-Khah D, Chan K, Postow M, Bass A. Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors? ACR Convergence, November 2021
For more publications, please see the PubMed listing.
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of December 22, 2020, Dr. Bass reported no relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.